BRPI0506765A - composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição - Google Patents

composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição

Info

Publication number
BRPI0506765A
BRPI0506765A BRPI0506765-0A BRPI0506765A BRPI0506765A BR PI0506765 A BRPI0506765 A BR PI0506765A BR PI0506765 A BRPI0506765 A BR PI0506765A BR PI0506765 A BRPI0506765 A BR PI0506765A
Authority
BR
Brazil
Prior art keywords
substituted
compound
phenyl
lower alkyl
composition
Prior art date
Application number
BRPI0506765-0A
Other languages
English (en)
Inventor
Lynn Resnick
Donna M Huryn
Joan E Sabalski
Joshua D Berkowitz
Anthony Frank Kreft
Dennis Martin Kubrak
Thomas Joseph Caggiano
Koi Michele Morris
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0506765A publication Critical patent/BRPI0506765A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

COMPOSTO OU UM SEU SAL, HIDRATO E/OU PRó-DROGAFARMACêUTICAMENTE ACEITáVEIS, COMPOSIçãO FARMACêUTICA, MéTODOS PARA INIBIR A PRODUçãO DE BETA-AMILóIDE EM UM PACIENTE E PARA TRATAR DE UMA DOENçA, KIT FARMACêUTICO, USO DE UM COMPOSTO OU DE UMA COMPOSIçãO Composto úteis para reduzir os níveis da beta - amilióde são providos. Os compostos têm a estrutura de fórmula Ia: em que R~ 1~ é alquila inferior, alquila inferior substituída fenila,fenila substituída, benzila, benzila substituída, benzilóxi, benzilóxi substituído, ou SO~ 2~ R~ 5~; R~ 5~ é fenila, fenila substituída, heterociclo, heterociclo susbstituído, alquila ou alquila substituída; R~ 2~é alquila inferior, alquila inferior substituída, CF~ 3~ alquenila, alquenila substituída, alquinila, alquinila substitúida, fenila, fenila substituída ou cicloalquila;R~ 3~ é hidrogênio, alquila inferior ou alquila inferior substituída; R~4~ é fenila, fenila substituída, heteroclico, heteroclicosubstituído, tiofeno ou tiofeno substituído; R~ 6~ é hidrogênio, alquila inferior, alquila inferior substituída, CF~ 3~, alquenila, alquenila substituída,alquinila,alquinila substituída, fenila, fenila substituída, cicloalquila ou cicloalquila substituída W,X,Y são independentes CR~ 7~ ou N; e R~ 7~ é hidrogênio, halogênio, alquila inferior ou alquila inferior substituída
BRPI0506765-0A 2004-01-16 2005-01-13 composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição BRPI0506765A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53708604P 2004-01-16 2004-01-16
PCT/US2005/001082 WO2005073198A1 (en) 2004-01-16 2005-01-13 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole

Publications (1)

Publication Number Publication Date
BRPI0506765A true BRPI0506765A (pt) 2007-05-22

Family

ID=34825912

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506765-0A BRPI0506765A (pt) 2004-01-16 2005-01-13 composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição

Country Status (11)

Country Link
US (3) US7399778B2 (pt)
EP (1) EP1709003B1 (pt)
JP (1) JP2007517905A (pt)
CN (1) CN1910158A (pt)
AT (1) ATE443701T1 (pt)
AU (1) AU2005207835A1 (pt)
BR (1) BRPI0506765A (pt)
CA (1) CA2552558A1 (pt)
DE (1) DE602005016775D1 (pt)
ES (1) ES2330451T3 (pt)
WO (1) WO2005073198A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2321394C2 (ru) * 2002-06-11 2008-04-10 Уайт Замещенные фенилсульфонамидные ингибиторы продуцирования бета-амилоида
WO2004092155A1 (en) * 2003-03-31 2004-10-28 Wyeth Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
CA2552558A1 (en) * 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
MXPA06014909A (es) * 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
RU2008129797A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Способы получения сульфонамид-замещенных спиртов и их промежуточных соединений
CN101384579A (zh) * 2006-02-17 2009-03-11 惠氏公司 2-氨基三氟烷基取代的醇的选择性n-磺酰化
EP2013184A1 (en) * 2006-04-21 2009-01-14 AstraZeneca AB Sulfonamide compounds useful as edg receptor modulators
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
CA2649396A1 (en) * 2006-04-21 2007-11-08 Wyeth Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
CA2667802A1 (en) * 2006-11-03 2008-05-29 Northwestern University Multiple sclerosis therapy
CL2008002059A1 (es) * 2007-07-16 2008-11-14 Wyeth Corp Método de preparación de sulfonamidas heterocíclicas; los compuestos intermediarios usados en el método descrito; y los métodos de preparación de dichos intermediarios.
EP2193117A1 (en) * 2007-07-16 2010-06-09 Wyeth a Corporation of the State of Delaware Inhibitors of beta amyloid production
AR067534A1 (es) * 2007-07-16 2009-10-14 Wyeth Corp Proceso para la preparacion de trifluoroalquil - fenil sulfonamidas y de sulfonamidas heterociclicas
AR070120A1 (es) * 2008-01-11 2010-03-17 Wyeth Corp Derivados de aril sulfonamida que contienen o-sulfato y o-fosfato, utiles como inhibidores de beta-amiloide, proceso de preparacion de los mismos y composiciones farmaceuticas que los contienen.
CA2718411C (en) 2008-03-27 2016-02-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
MX2012003207A (es) 2009-09-18 2012-05-29 Chase Pharmaceuticals Corp Metodo y composicion para tratar la demencia de tipo alzheimer.
JP2011043839A (ja) * 2010-09-29 2011-03-03 Panasonic Corp レジスト材料及びそれを用いたパターン形成方法
CN102786447A (zh) * 2011-08-01 2012-11-21 四川大学 N,n-二取代芳基磺酰胺类化合物及其制备方法和用途
CN104768540A (zh) 2012-09-05 2015-07-08 才思制药公司 抗胆碱能神经保护组合物和方法
CA2951784C (en) * 2014-06-10 2022-05-31 Ube Industries, Ltd. N-substituted sulfonamide compound and method for producing same
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
JP6572890B2 (ja) 2014-06-10 2019-09-11 宇部興産株式会社 ヘテロ芳香族スルホンアミド化合物の製造方法
WO2016179558A1 (en) 2015-05-06 2016-11-10 The Regents Of The University Of California K-ras modulators
CA3059943A1 (en) 2017-04-20 2018-10-25 The Regents Of The University Of California K-ras modulators
WO2019204505A2 (en) * 2018-04-18 2019-10-24 Theras, Inc. K-ras modulators with a vinyl sulfonamide moiety

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200209D0 (en) * 1992-01-07 1992-02-26 British Bio Technology Compounds
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
NZ264143A (en) 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
CA2238175A1 (en) * 1995-11-28 1997-06-19 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
HUP0001383A3 (en) 1996-11-22 2001-11-28 Lilly Co Eli N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions comprising same and their use
WO1999012910A1 (fr) * 1997-09-11 1999-03-18 Nissan Chemical Industries, Ltd. Composes a base de pyrazole et agent de lutte contre les maladies vegetales
AU773273B2 (en) 1999-02-26 2004-05-20 Bristol-Myers Squibb Company Novel sulfonamide compounds and uses thereof
BR0013143A (pt) * 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1222176A1 (en) 1999-10-08 2002-07-17 Bristol-Myers Squibb Pharma Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
JP2003528076A (ja) 2000-03-20 2003-09-24 メルク シャープ エンド ドーム リミテッド スルホンアミド置換架橋ビシクロアルキル誘導体
AU2001264872A1 (en) * 2000-06-05 2001-12-17 Ortho-Mcneil Pharmaceutical, Inc. Method for synthesis of substituted azole libraries
NZ526213A (en) * 2000-12-13 2005-05-27 Wyeth Corp Heterocyclic sulfonamide inhibitors of beta amyloid production
US6657070B2 (en) * 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
JP4615861B2 (ja) 2001-12-11 2011-01-19 ワイス・エルエルシー キラル的に純粋なα−アミノ酸およびＮ−スルホニルα−アミノ酸の生産
DE10163582A1 (de) * 2001-12-21 2003-07-03 Thomson Brandt Gmbh Automatische Verstärkungsregelung für einen Tuner
WO2004092155A1 (en) * 2003-03-31 2004-10-28 Wyeth Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
CA2552558A1 (en) * 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole

Also Published As

Publication number Publication date
CN1910158A (zh) 2007-02-07
ES2330451T3 (es) 2009-12-10
EP1709003A1 (en) 2006-10-11
US20100144812A1 (en) 2010-06-10
DE602005016775D1 (de) 2009-11-05
CA2552558A1 (en) 2005-08-11
ATE443701T1 (de) 2009-10-15
US7674813B2 (en) 2010-03-09
AU2005207835A1 (en) 2005-08-11
EP1709003B1 (en) 2009-09-23
US20080249150A1 (en) 2008-10-09
US7399778B2 (en) 2008-07-15
WO2005073198A1 (en) 2005-08-11
US20050171180A1 (en) 2005-08-04
JP2007517905A (ja) 2007-07-05

Similar Documents

Publication Publication Date Title
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
ATE537175T1 (de) Neue piperazino-dihydrothienopyrimidin-derivate
NO20076418L (no) Heterocyclic compounds as agonists for the thyroid receptor
NZ595829A (en) 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives
TW200612956A (en) Dihydropteridinones for the treatment of cancer diseases
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
ECSP055867A (es) Derivados de pirrolopirimidina
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
IL185844A0 (en) I-acetic acid-indole derivatives with pgd2 antagonist activity
NO20055655D0 (no) Anvendelse av azetidinkarboksamidderivater i terapi
EA200701780A1 (ru) Противоопухолевое средство
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
NO20072409L (no) Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
ATE384058T1 (de) Thiazolderivate
HK1138262A1 (en) Novel phosphodiesterase inhibitors
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
SE0401342D0 (sv) Therapeutic compounds
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.